Trial Search Results
Phase 1-2 Vatalanib and Gemcitabine in Advanced Pancreatic Cancer
The purpose of the study is to determine the optimal safe and tolerable dose of gemcitabine in combination with once daily or twice daily dose of PTK/ZK in patients with unresectable pancreatic cancer. The Phase II part of this study planned to determine the antitumor activity of this regimen and its effectiveness of preventing tumor growth and spread.
Stanford is currently not accepting patients for this trial.